Separation and Related Costs

[Table of Contents](#i769337f517694ce29a72abc52f207787_10)  
Notes to Consolidated Financial Statements — (Continued)Becton, Dickinson and Company  
  
  


|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| (Millions of dollars) | 2021 |  | 2020 |  | 2019 |
| Income Before Income Taxes |  |  |  |  |  |
| Medical (a) (b) (c) | $ | 2,583  |  |  | $ | 2,274  |  |  | $ | 2,824  |  |
| Life Sciences (d) | 2,391  |  |  | 1,405  |  |  | 1,248  |  |
| Interventional (e) | 933  |  |  | 724  |  |  | 903  |  |
| Total Segment Operating Income | 5,907  |  |  | 4,403  |  |  | 4,976  |  |
| Acquisitions and other restructurings | (185) |  |  | (309) |  |  | (480) |  |
| Unallocated other operating expense, net (f) | (238) |  |  | (363) |  |  | (579) |  |
| Net interest expense | (460) |  |  | (521) |  |  | (627) |  |
| Other unallocated items (g) | (2,783) |  |  | (2,224) |  |  | (2,115) |  |
| Total Income Before Income Taxes | $ | 2,242  |  |  | $ | 985  |  |  | $ | 1,176  |  |
| Capital Expenditures |  |  |  |  |  |
| Medical | $ | 777  |  |  | $ | 477  |  |  | $ | 577  |  |
| Life Sciences | 297  |  |  | 192  |  |  | 230  |  |
| Interventional | 125  |  |  | 119  |  |  | 120  |  |
| Corporate and All Other | 32  |  |  | 22  |  |  | 30  |  |
| Total Capital Expenditures | $ | 1,231  |  |  | $ | 810  |  |  | $ | 957  |  |
| Depreciation and Amortization |  |  |  |  |  |
| Medical | $ | 1,140  |  |  | $ | 1,104  |  |  | $ | 1,073  |  |
| Life Sciences | 352  |  |  | 286  |  |  | 284  |  |
| Interventional | 769  |  |  | 750  |  |  | 881  |  |
| Corporate and All Other | 12  |  |  | 14  |  |  | 14  |  |
| Total Depreciation and Amortization | $ | 2,273  |  |  | $ | 2,154  |  |  | $ | 2,253  |  |

(a)The amounts in 2021 and 2020 include charges of $56 million and $244 million, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for BD AlarisTM infusion pumps in the Medication Management Solutions unit. (b)The amount in 2020 included $41 million of charges to Cost of products sold to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units.(c)The amount in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.(d)The amount in 2020 included charges of $57 million recorded to Cost of products sold to write down the carrying value of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units.(e)The amount in 2019 included a charge of $30 million recorded to Research and development expense to write down the carrying value of certain intangible assets in the Surgery unit.(f)The amounts in 2021, 2020 and 2019 include pre-tax charges of $361 million, $378 million and $914 million, respectively, related to certain product liability matters, which is further discussed in Note 5. The amount in 2021 also includes gains of $158 million on sale-leaseback transactions, which are further discussed in Note 17, and $35 million of costs incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business. The 2019 amount also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million, which is further discussed in Note 10.76
